Wells Fargo & Company Prelude Therapeutics Inc Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRLD
# of Institutions
62Shares Held
33.9MCall Options Held
400Put Options Held
100-
Orbimed Advisors LLC San Diego, CA10.9MShares$14.4 Million1.0% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$13.4 Million0.51% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$5.46 Million0.33% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$3.39 Million0.54% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.41 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $48M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...